Author(s)

Berry Ikolango Bongenya^1,2, Marie-Thérèse Ayanne Safi Sombo³, Guy Makila Mabe Bumoko³, Benoit Obel Kabengele⁴, Mariano Manzo Lusakibanza⁵, Gauthier Kahunu Mesia⁵, Erick Ntambwe Kamangu^2,6*

¹Faculty of Medicine, Bel Campus Technological University, Kinshasa, Democratic Republic of the Congo.
²“HIV/AIDS Focus” Research Group, Kinshasa, Democratic Republic of the Congo.
³Department of Neurology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
⁴Department of Internal Medicine, University Clinic, Faculty of Medicine, University of Kinshasa, Democratic Republic of the Congo.
⁵Clinical Pharmacology Service, Department of Pharmacovigilance, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
⁶Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Context: Two years after the transition to Dolutegravir (DTG), at the national level, data on compliance with the execution of this transition and the rational use of the new molecule are not available. Objective: The objective of this study was to determine compliance with first-line ART prescriptions among People Living with HIV starting AntiRetroViral treatment in Kinshasa during the Dolutegravir era. Methods: This study is a descriptive cross-sectional study to determine compliance with first-line ART prescriptions among people living with HIV during the Dolutegravir era in Kinshasa. Sixteen Outpatients Treatment Centers (OTCs) were included in the study for their expertise in the care of PLHIV, their technical collection platform and their accessibility. The parameters of interest were: age, sex, outpatient treatment centers, and medical prescription. Results: One hundred and nineteen (119) patients were included in this work in accordance with the inclusion criteria; 67 (56.3%) are female, giving a sex ratio of 1.29 in favor of women. The average age of the patients included is 39.87 ± 12.36 years with extremities of 18 to 69 years. The most represented age group is that of 36 to 45 years with 37 patients (31.9%). One hundred and nineteen (119) patients were received from 16 centers in Kinshasa, according to 6 OTC for the district of Funa, 4 OTC for Tshangu and 3 OTC respectively for Lukunga and Mont-Amba. All the centers respect the new recommendations of the National Program; all patients (100%) are on the Tenofovir (TDF) + Lamivudine (3TC) + Dolutegravir (DTG) combination. Conclusion: Compliance with the prescription of DTG as a first-line ARV in the DRC is effective in the city province of Kinshasa.

ART Profile, Dolutegravir, Kinshasa

Bongenya, B. , Sombo, M. , Bumoko, G. , Kabengele, B. , Lusakibanza, M. , Mesia, G. and Kamangu, E. (2023) Compliance with First-Line AntiRetroViral Treatment (ART) for HIV Infection in the Era of Dolutegravir in Kinshasa, Democratic Republic of the Congo. World Journal of AIDS, 13, 11-17. doi: 10.4236/wja.2023.131002.